|Articles|August 24, 2022
physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health
New partnership will accelerate Phase III study in patients with atrial fibrillation.
Advertisement
physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.
Read more about the new partnership
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Breaking Out of AI Pilot Mode in Clinical Development
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
5